-
Latest News
- Reduced heart rate variability predicts fatigue severity in individuals with CFS/ME
- Recovering from CFS as an intra-active process
- A neuro-inflammatory model can explain the onset, symptoms and flare-ups of ME/CFS
- Paediatric patients with ME/CFS value understanding & help to move on with their lives
- The role of low-grade inflammation in ME/CFS – associations with symptoms
Archives
Tag Archives: Prof Olav Mella
B-Lymphocyte depletion in patients with ME/CFS: the final rituximab trial results
B-lymphocyte depletion in patients With Myalgic Encephalomyelitis/ Chronic Fatigue Syndrome: a randomized, double-blind, placebo-controlled trial by Oystein Fluge, Ingrid G. Rekeland, Katarina Lien, Hanne Thurmer, Petter C. Borchgrevink, Christoph Schafer, Kari Sorland, Jorg Assmus, Irini Ktoridou-Valen, Ingrid Herder, Merethe E. … Continue reading
Posted in News
Tagged B-lymphocyte depletion, Dr Oystein Fluge, Dr Peter Rowe, Prof Olav Mella, rituxan, rituximab
Comments Off on B-Lymphocyte depletion in patients with ME/CFS: the final rituximab trial results
Immunosignature analysis of ME/CFS – promising diagnostic biomarker
Immunosignature Analysis of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) Oliver P Günther, Jennifer L Gardy, Phillip Stafford, Øystein Fluge, Olav Mella, Patrick Tang, Ruth R Miller, Shoshana M Parker, Stephen A Johnston, David M Patrick in Molecular Neurobiology (2018) pp 1-9 [Published online: … Continue reading
Posted in News
Tagged biomarker, diagnostic marker, Dr David Patrick, Dr Oystein Fluge, immune dysfunction, immunosignature, Jennifer L Gardy, Oliver P Günther, Patrick Tang, Phillip Stafford, Prof Olav Mella, Ruth R Miller, Shoshana M Parker, Stephen A Johnston
Comments Off on Immunosignature analysis of ME/CFS – promising diagnostic biomarker
Norwegian rituximab trial reports negative results
The Norwegian Rituximab trial reports negative results ahead of the publication of the full results. Attempts are now under way to determine the best way forward in understanding what has been learned and how to find out which patients may still benefit from … Continue reading
Posted in News
Tagged B-cell, Cort Johnson, Cyclophosphamide, Dr Oystein Fluge, Prof Olav Mella, rituximab, Simmaron Research
Comments Off on Norwegian rituximab trial reports negative results
Norwegian Rituximab studies update
Helse Bergen blog post, 29 Sep 29017: RituxME B-lymphocyte depletion using the anti-CD20 antibody rituximab (Mabthera®) in Myalgic Encephalopathy/Chronic Fatigue Syndrome (“RituxME”) RituxME is a multicentre study conducted in five study centres in Norway: the Oncology Department at Haukeland University … Continue reading
Posted in News
Tagged antibodies, Dr Oystein Fluge, Norway, Prof Olav Mella, rituximab, RituxME
Comments Off on Norwegian Rituximab studies update
New rituximab trial results from Norway
Research abstract: Myalgic Encephalopathy/Chronic Fatigue Syndrome (ME/CFS) is a disease of unknown etiology. We have previously suggested clinical benefit from B-cell depletion using the monoclonal anti-CD20 antibody rituximab in a randomized and placebo-controlled study. Prolonged responses were then demonstrated in … Continue reading
Posted in News
Tagged B-cell, Dr Oystein Fluge, Norway, Prof Olav Mella, rituximab, T-cell
Comments Off on New rituximab trial results from Norway
Cancer doctor Dagfinn Øgreid has treated ME patients with rituximab
Blog article: Offers private ME treatment with cancer drugs – scientists react, by Anne Grete Storvik, Nov 23 2015 in Dagensmedicin [ translated by Google translate] A private clinic in Sandnes offers treatment for ME with the cancer drug rituximab. Patients pay … Continue reading
Posted in News
Tagged autoimmune disorders, Dr Dagfinn Øgreid, Dr Oystein Fluge, immunomodulatory drug, Norway, Prof Olav Mella, rituximab
1 Comment
UK rituximab trial fundraising total almost reached
Invest in ME has announced the latest fundraising total for the rituximab/B-cell research, which is a great boost as the research team at UCL are about to visit and discuss the subject with Dr Fluge and Professor Mella in Haukeland University Hospital, … Continue reading
Posted in News
Tagged B-cell, Dr Oystein Fluge, IiME, Invest in ME, Prof Olav Mella, rituximab, UCL, University College London
Comments Off on UK rituximab trial fundraising total almost reached
